BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38140901)

  • 1. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
    Odouard IC; Anderson GF; Alexander GC; Ballreich J
    J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
    Glynn A; Hernandez I; Roberts ET
    Health Serv Res; 2022 Oct; 57(5):1136-1144. PubMed ID: 35430735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
    Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
    J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations Between Annual Medicare Part D Low-Income Subsidy Loss and Prescription Drug Spending and Use.
    Fung V; Price M; Cheng D; Patel TA; Yang Z; Hsu J; Alegria M; Newhouse JP
    JAMA Health Forum; 2024 Feb; 5(2):e235152. PubMed ID: 38306091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Out-of-Pocket Costs for Long-Acting Injectable and Oral Antipsychotics Among Medicare Patients With Schizophrenia.
    Doshi JA; Li P; Geng Z; Seo S; Patel C; Benson C
    Psychiatr Serv; 2024 Apr; 75(4):333-341. PubMed ID: 37960866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
    Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
    Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
    Yazdany J; Tonner C; Schmajuk G
    Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1210-1218. PubMed ID: 25776035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
    Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
    JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
    Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
    JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an out-of-pocket maximum in Medicare Part D.
    Parasrampuria S; Anderson GF
    Am J Manag Care; 2022 Feb; 28(2):e55-e62. PubMed ID: 35139297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of prescription drug expenditures and medication adherence among medicare part D beneficiaries with and without the low-income supplement.
    Yala SM; Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF
    BMC Health Serv Res; 2014 Dec; 14():665. PubMed ID: 25526892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
    Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
    Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing patient OOP spending for specialty drugs in Medicare Part D and employer-sponsored insurance.
    Parasrampuria S; Sen AP; Anderson GF
    Am J Manag Care; 2020 Sep; 26(9):388-394. PubMed ID: 32930551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognition and take-up of subsidized drug benefits by Medicare beneficiaries.
    Kuye IO; Frank RG; McWilliams JM
    JAMA Intern Med; 2013 Jun; 173(12):1100-7. PubMed ID: 23649604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
    Park J; Look KA
    Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
    Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
    JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
    Blumberg DM; Prager AJ; Liebmann JM
    JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
    Patel UD; Davis MM
    J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-gap discounts in Medicare Part D and specialty drug use.
    Jung J; Xu WY; Cheong C
    Am J Manag Care; 2017 Sep; 23(9):553-559. PubMed ID: 29087157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
    Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
    J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.